NCT06889857View on ClinicalTrials.gov

Safety and Efficacy of Intravenous Administration of SHED-CM for ALS

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 5, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIOLOGICAL

The study drug is SHED-CM manufactured by U-Factor

This study will involve informed consent, a 12-week observation period, a 12-week study drug administration period, and a 4-week follow-up period.

Trial Locations (1)

102-0085

Hitonowa Medical, Chiyoda City

Sponsors

Lead Sponsor

Hitonowa Medical
All Listed Sponsors
collaborator

U-Factor Co.,Ltd.

UNKNOWN

lead

Hitonowa Medical

OTHER